VCA
HAE icon

Verdence Capital Advisors’s Haemonetics HAE Stock Holding History

Verdence Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,313
Closed -$506K – 699
2025
Q4 		$506K Sell
6,313
-1,887
-23% -$127K 0.03% 425
2025
Q3 		$420K Buy
8,200
+1,984
+32% +$123K 0.02% 501
2025
Q2 		$464K Buy
6,216
+214
+4% +$14.2K 0.03% 446
2025
Q1 		$381K Buy
6,002
+2,229
+59% +$152K 0.03% 469
2024
Q4 		$295K Buy
3,773
+11
+0.3% +$884 0.02% 520
2024
Q3 		$302K Buy
+3,762
New +$304K 0.02% 517

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verdence Capital Advisors's HAE Position: Q1 2026 in Review

Verdence Capital Advisors sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 6,313 shares — an estimated $506K sold.

Verdence Capital Advisors first reported a position in HAE in Q3 2024 and held it in 6 quarters. The position peaked at $506K in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Verdence Capital Advisors reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
  • Verdence Capital Advisors sold 6,313 Haemonetics shares in Q1 2026, an estimated $506K.
  • Verdence Capital Advisors first reported a position in Haemonetics in Q3 2024 and held it in 6 quarters.
  • Verdence Capital Advisors's Haemonetics position peaked at $506K in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.